These evidence all imply that the increase of asprosin might be a culprit responsible for lower extremity PAD in obesity or diabetic patients, and this effect would not be relied on its regulation on metabolism itself but depend on the local action on arteries. This evidence concerns the gene FBN1 and obesity due to melanocortin 4 receptor deficiency.